University Of Michigan
Ann Arbor, Michigan, 48109, United States
NCT Number: NCT03617185
The purpose of this research study is to evaluate how exercise and surgical weight loss affect how likely an individual is to develop peripheral neuropathy and other neurologic complications.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Not applicable
Ann Arbor, Michigan, 48109, United States
The length of this study, including screening is approximately 24 months. Patients at Bariatric Surgery Clinics will be recruited for this study. Both patients that decide to undergo bariatric surgery, and those that do not undergo surgery will be enrolled. Patients will be randomized to either a high intensity interval training (HIIT) or standard exercise regimen after eligibility is confirmed and the baseline visit is complete. All patients will complete follow-up appointments at 3 month, 12 months and 24 months. Patients that are randomized to the HIIT program will compete 2 supervised and 1 unsupervised training sessions a week for 24 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
Patients will undergo bariatric surgery as part of their routine care
Time frame: Baseline, 3 months, 12 months and 24 months
Intraepidermal Nerve Fiber Density (IENFD) as assessed by 3mm skin biopsies at the proximal thigh.
Time frame: Baseline, 3 months, 12 months and 24 months
Intraepidermal Nerve Fiber Density (IENFD) as assessed by 3mm skin biopsies at the distal leg.
Time frame: Baseline, 3 month, 12 months and 24 months
Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.
Corneal Nerve Fiber Density are quantified by fibers/mm2, a higher number represents a higher density of fibers. Lower numbers indicate worse neuropathy.
Time frame: Baseline, 3 month, 12 months and 24 months
Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.
Corneal Nerve Branch Density are quantified by branches/mm2, a higher number represents a higher density of branches. Lower numbers indicate worse neuropathy.
Time frame: Baseline, 3 month, 12 months and 24 months
Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.
Corneal Nerve Fiber Length are quantified by mm/mm2, a higher number represents a higher total length of fibers. Lower numbers indicate worse neuropathy .
Time frame: Baseline, 3 month, 12 months and 24 months
Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.
Tortuosity Coefficient represents the total tortuosity (twisting/bending of nerves). As a coefficient the value is unitless, a higher value represents greater tortuosity. Lower numbers indicate worse neuropathy.
Time frame: Baseline, 3 month, 12 months and 24 months
24-2 FDT was used to evaluate retinopathy using visual field deficits. Mean Deviation is presented below.
Mean deviation is the average difference from normal expected value in the patients' particular age group. Lower values indicate more visual deficit. Higher values indicate fewer visual deficit.
Time frame: Baseline, 3 month, 12 months and 24 months
24-2 FDT was used to evaluate retinopathy using visual field deficits. Foveal sensitivity is presented below.
Foveal sensitivity is the measurement of the fovea's light detection ability. Lower values suggest visual field deficits.
Time frame: Baseline, 3 month, 12 months and 24 months
24-2 FDT was used to evaluate retinopathy using visual field deficits. Pattern SD (PSD) is presented below.
PSD provides information about localized loss. A higher PSD indicates a non-uniform sensitivity loss and visual field deficit.
Time frame: Baseline, 3 month, 12 months and 24 months
As assessed by fundus photographs, participants were identified as either having retinopathy or not having retinopathy. Data is shown as number of people with retinopathy at a particular study visit.
Time frame: Baseline and 24 months
Latency measures the time in millisecond between stimulation and the recording electrode. Was performed on sural, peroneal, and tibial nerves. No response and abnormal values indicate neuropathy.
Time frame: Baseline and 24 months
Amplitude measures the height of electrical signal (waveform) in millivolts produced by the stimulated motor nerve. Was performed on peroneal, and tibial nerves. No response and abnormal values indicate neuropathy.
Time frame: Baseline and 24 months
Amplitude measures the height of electrical signal (waveform) in microvolts produced by the stimulated sensory nerve. Was performed on sural nerve. No response and abnormal values indicate neuropathy.
Time frame: Baseline and 24 months
Conduction velocity (V) measures the speed (m/s) at which the electrical impulse travels along the nerve. Was performed on peroneal nerves. No response and abnormal values indicate neuropathy. Abnormal values are <36 or 39, depending on whether certain criteria applied to the participant. Data was not analyzed separately.
Time frame: Baseline and 24 months
F wave index measures the time in millisecond between stimulation at a distal (near the muscle) point and for the stimulus to travel to the spinal cord and back, allowing to assess the entire length of the nerve.
Was performed on peroneal, and tibial nerves. No response and abnormal values indicate neuropathy.
Time frame: Baseline and 24 months
Deep breathing/exhalation to inhalation (E:I) ratio were evaluated using PS monitor software. Values < 1 are abnormal, indicative of cardiovascular autonomic neuropathy
Time frame: Baseline and 24 months
Postural change-30:15 ratio was evaluated using PS monitor software. Values < 1 are abnormal, indicative of cardiovascular autonomic neuropathy
Time frame: Baseline and 24 months
Valsalva ratio was evaluated using PS monitor software. Values <= 1.10 are abnormal, indicative of cardiovascular autonomic neuropathy
Time frame: 24 months
Toronto definition of probable neuropathy is having at least 2 out of 3 of the following: abnormal sensory examination, reflexes, and patient-reported symptoms. Data is reported as number of participants who, under the Toronto definition, were identified as having probable polyneuropathy.
Time frame: Baseline, 3 month, 12 months and 24 months
MNSI questionnaire is scored from 0-15, score > 4 indicate neuropathy, higher scores indicate worse neuropathy.
A score of 1 point is given for answers of "yes" for questions 1-6, 8-12, 14, and 15 and "no" for questions 7 and 13.
Time frame: Baseline, 3 month, 12 months and 24 months
MNSI exam is scored from 0-8, score >= 2.5 indicate neuropathy. Higher scores indicate worse neuropathy.
Time frame: Baseline, 3 month, 12 months and 24 months
The Michigan Neuropathy Screening Instrument (MNSI) index is a weighted composite score computed using the sum of the b-coefficients for all items within the MNSI questionnaire (15 questions) and MNSI exam (4 physical/visual exam).
Range: -0.93, 7.39 Values > 2.5407 are indicative of clinical neuropathy
Time frame: Baseline, 3 month, 12 months and 24 months
UENS is a composite score with five sections measuring multiple clinical measures of nerve injury. Sections are scored separately for each side (Right vs Left), and the total score is the sum across everything. Range: 0-42, higher score represents more severe polyneuropathy.
Time frame: Baseline, 3 month, 12 months and 24 months
mTNS is a scale of 0-33 that measures neuropathy symptoms and exam findings. Higher scores indicate more severe polyneuropathy.
Time frame: Baseline, 3 month, 12 months and 24 months
SAS evaluates the presence and magnitude of autonomic symptoms. Total impact score ranges from 0-60 (or up to 55 for participants to whom certain criteria did not apply). Higher score indicates worse autonomic neuropathy
Time frame: Baseline, 3 month, 12 months and 24 months
DNS is a questionnaire of neuropathy symptoms. Score ranges 0-4, >/=1 indicates polyneuropathy. 0 indicates no polyneuropathy.
Time frame: Baseline, 3 months, 12 months, 24 months
Sum of the sensory score (0-30) and affective score (0-15) for a total score of 0-45. A higher score represents greater pain present.
Time frame: Baseline, 3 months, 12 months, 24 months
Participant reported pain scale with range 0-10, higher score indicates more pain.
Time frame: Baseline, 3 months, 12 months, and 24 months
Neuropathy Quality of Life (NeuroQOL) evaluates symptoms and function in regard to quality of life over the past four weeks. Range 1-15, higher score indicates neuropathy having a greater impact on quality of life.
Time frame: Baseline, 3 months, 12 months, and 24 months
This test measures in seconds how long it takes the participant to stand up from a seated position, walk around a cone places 8 feet away, and return to the chair and sit down. Less time indicates better speed, agility, and balance when moving.
Time frame: Baseline, 3 months, 12 months, and 24 months
Berg Balance Scale measures participants' ability to balance and avoid falls. Scores range from 0-56, higher score indicates less likely to fall.
Time frame: Baseline, 3 months, 12 months, and 24 months
Patient response indicating if they have fallen in the last year. Data is shown as number of people who have fallen in the last year.
Time frame: Baseline, 3 months, 12 months, and 24 months
Neurothesiometer is placed on the bottom of the great toe, and slowly increased until participant reports they can feel the vibration. The greater the microns, the less feeling the participant has, suggestive of worse sensory function.
Value > 25 Microns is indicative of neuropathy. There is no known maximum range. Lower values indicate better sensory function.
Time frame: Baseline and at 24 months
NIH Toolbox Cognition Fluid (Range: 0-100) - Composite score derived as an average across five cognitive domains.
It's a fully adjusted T-score comparing the participant to a nationally representative sample, stratified by age and other demographics.
Individual domain scores are fully adjusted T score with range 0-100 and measures the following-
A T-score of 50 represents the population mean. A score of 60 indicates that the participant is 1 SD above the national average for individuals with similar demographic characteristics
Higher scores reflect better cognitive functionality. No set clinical threshold, scores above mean indicate above average cognition for a given age group.
Time frame: Baseline and at 24 months
Used to evaluate verbal learning and memory using a list of 15 unrelated words presented to the participant over repeat trial.
Includes 3 independent scales:
No set clinical threshold, scores above mean indicate above average cognition for a given age group.
University of Michigan
Other
The Effect of High Intensity Interval Training and Surgical Weight Loss on Distal Symmetric Polyneuropathy Outcomes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06040567
Abnormalities, Multiple, Autoimmune Diseases
Copenhagen, Denmark
View Trial DetailsNCT05023889
Amyloid Neuropathies, Amyloid Neuropathies, Familial
Austin, Texas, United States
View Trial DetailsNCT07493681
Nervous System Diseases, Neuromuscular Diseases
Milan, MI, Italy
View Trial DetailsNCT03237494
Amyloid Neuropathies, Amyloid Neuropathies, Familial
Linz, Austria
View Trial Details